Can-Fite BioPharma Ltd.
CANF
$1.23
-$0.03-2.38%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 674.00K | 650.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 674.00K | 650.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 674.00K | 650.00K | -- | -- | -- |
| SG&A Expenses | 3.05M | 3.01M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.80M | 8.60M | -- | -- | -- |
| Operating Income | -8.13M | -7.95M | -- | -- | -- |
| Income Before Tax | -7.88M | -7.57M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.88 | -7.57 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.88M | -7.57M | -- | -- | -- |
| EBIT | -8.13M | -7.95M | -- | -- | -- |
| EBITDA | -8.12M | -7.94M | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | -- | -- | -- |
| Normalized Basic EPS | 0.00 | 0.00 | -- | -- | -- |
| EPS Diluted | 0.00 | 0.00 | -- | -- | -- |
| Normalized Diluted EPS | 0.00 | 0.00 | -- | -- | -- |
| Average Basic Shares Outstanding | 8.70B | 7.66B | -- | -- | -- |
| Average Diluted Shares Outstanding | 8.70B | 7.66B | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |